Provention Bio

188 articles about Provention Bio

• Provention Bio Appoints Leading T1D Expert, Dr. Mark Rigby, as Vice President, Clinical Development

  7/31/2018

  Provention strengthens its strategic platform in type 1 diabetes (T1D) interception and prevention

• Provention Bio Announces Closing of Upsized Initial Public Offering

  7/19/2018

  Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the closing of its initial public offering of shares of its common stock at a public offering price of $4.00 per share on July 19, 2018.

• Provention Bio Announces Agreements with MacroGenics for Two Clinical-Stage Assets for the Treatment of Autoimmune Disorders

  5/9/2018

  Provention acquires PRV-031 and plans to initiate pivotal Phase 3 clinical trial to intercept early-onset type 1 diabetes, a pediatric orphan indication

• Provention Bio Completes Its Executive Management Team

  9/28/2017

• New Kid on the Block Provention Bio Snags 2 Clinic-Ready Immune Compounds From Johnson & Johnson

  9/21/2017

• Provention Bio Announces Clinical Program Focused On Intercepting And Preventing The Onset Of Type 1 Diabetes

  7/18/2017

• Provention Bio Appoints Eleanor L. Ramos, MD, As Chief Medical Officer And Chief Operating Officer

  7/11/2017

• Provention Bio Secures $28.4 Million Founding Financing To Fund Development Targeting The Interception And Prevention Of Immune-Mediated Disease

  6/26/2017